12,372 trials
Refractory Partial Seizures
Primary: Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) — -9.72; -30.52; -17.57 Percent Change
Prevention
Primary: Time From Randomization to Occurrence of Gastric and/or Duodenal Ulcers up to Data Cut-off Date for Interim Analysis. — 1; 16; 1; 4 Participants — p=<0.001
Impaired Fasting Glucose · Prediabetes
Primary: Acute Insulin Response (AIRg) to Intravenous Glucose — 1866; 1752 pmol/1*min
Polycystic Kidney, Autosomal Dominant · Polycystic Liver Disease · Hepatomegaly
Primary: Percent Change in Liver Volume — -5.0; 0.9 percent change — p=0.048
Lower Back Pain
Primary: Subject Rated Change Relief From Starting Backache of Pain on a 100-point Visual Analog Scale — 16.4; 15.5; 15.2 mm
Psoriasis
Primary: Number of Participants Achieving a Greater Than or Equal to 75 Percentage Improvement From Baseline in Psoriasis Area and Severity Index (PASI 75) Score at Week 12…
Japanese Encephalitis
Primary: Geometric Mean Titer (GMT) for Anti-JEV Neutralizing Antibody — 160.8; 188.2; 168.4 titers
Major Depressive Disorder · Depression
Primary: Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment. — -12.7; -11.7 units on a scale — p=0.349
Major Depressive Disorder · Depression
Primary: Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment. — -12.1; -11.8; -11.3; -11.2 units on a scale — p=1.000
Japanese Encephalitis
Primary: Safety and Tolerability up to Day 56 — 58.9; 56.6 percentage of participants with AEs
Major Depressive Disorder · Depression
Primary: Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment. — -11.7; -11.6 units on a scale — p=0.944
Healthy Subjects · Partial Denture Wearers · Caries
Primary: Mean Percentage Surface Microhardness Recovery (%SMHR) of Enamel Specimens Exposed to NaF/Carbopol Toothpaste (1400 ppmF), NaF Toothpaste (1350ppmF) Compared to…
Pain
Primary: Change From Baseline in the Mean Box Scale-11 Pain Review Score at the End of Each Treatment Period (Each Lasting 14-20 Days) — -0.6; -0.6; 0.0 units on a scale — p=0.005
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection. — 56…
Gastrointestinal Neoplasm
Primary: Progression Free Survival